医学
临床意义
相关性(法律)
重症监护医学
外科
临床实习
药物治疗
梅德林
穿刺活检
放射科
作者
Bi-Yu Gao,Kai‐Lun Sheu
标识
DOI:10.1093/qjmed/hcaf312
摘要
The randomized trial by Liu et al. reported significant improvements in the Psoriasis Area and Severity Index (PASI) and itch scores with fire needle therapy for mild plaque psoriasis,1 yet several aspects of its clinical interpretation deserve closer scrutiny. The absolute PASI difference between the groups was small, and the low baseline severity meant that percentage-based responder metrics were more likely to reflect mathematical sensitivity than a meaningful reduction in lesions.1 This observation accords with evidence suggesting that conventional PASI thresholds may not accurately reflect clinical benefit in mild disease, where absolute change provides a clearer measure of patient impact.2 The greatest treatment difference occurred in symptom relief rather than objective clearance,1 implying that the therapy may act mainly on discomfort and sensory symptoms. In contemporary outcome studies of systemic agents, improvements in patient-reported outcomes generally parallel substantial objective gains, making this divergence noteworthy.3 Methodological considerations further limit interpretability. Sensory cues inherent in the application of fire needles probably compromised blinding,1 particularly for subjective endpoints such as the Visual Analogue Scale and the Dermatology Life Quality Index. Furthermore, quality-of-life outcomes were collected only up to mid-treatment, and recurrence data—prespecified in the protocol—were not reported,1 thereby constraining the assessment of durability. The long-term persistence of benefit is increasingly emphasized in psoriasis research and now informs the evaluation of therapeutic interventions across modalities.4,5 Collectively, these factors indicate that although a short-term symptomatic improvement was demonstrated, the long-term and unbiased treatment effect of fire needle therapy remains uncertain.
科研通智能强力驱动
Strongly Powered by AbleSci AI